Evolving Landscape of Biologic Therapy for Pediatric Psoriasis. Review uri icon

Overview

abstract

  • Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.

publication date

  • March 27, 2024

Research

keywords

  • Adalimumab
  • Biological Products
  • Dermatologic Agents
  • Psoriasis
  • Ustekinumab

Identity

Scopus Document Identifier

  • 85189073782

Digital Object Identifier (DOI)

  • 10.1016/j.det.2024.02.003

PubMed ID

  • 38796269

Additional Document Info

volume

  • 42

issue

  • 3